Suppr超能文献

初诊IV期前列腺癌患者治疗前血清25-羟基维生素D水平与生存率的关系

The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer.

作者信息

Gupta Digant, Trukova Kristen, Popiel Brenten, Lammersfeld Carolyn, Vashi Pankaj G

机构信息

Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center, Zion, Illinois, United States of America.

出版信息

PLoS One. 2015 Mar 16;10(3):e0119690. doi: 10.1371/journal.pone.0119690. eCollection 2015.

Abstract

BACKGROUND/AIMS: Emerging evidence in the literature suggests a positive association between serum 25-hydroxyvitamin D [25(OH)D], a standard indicator of vitamin D status, and survival in certain types of cancer. We investigated this relationship in newly diagnosed stage IV prostate cancer patients.

METHODS

A consecutive cohort of 125 newly diagnosed stage IV prostate cancer patients underwent a baseline serum 25(OH)D evaluation prior to receiving any treatment at our institution between January 2008 and December 2011. We used the vitamin D categories of "deficient (<20 ng/ml)", "insufficient (20 to 32 ng/ml)", and "sufficient (>32 ng/ml)". Cox regression was used to evaluate the prognostic significance of serum 25(OH)D after adjusting for relevant confounders.

RESULTS

Mean age at diagnosis was 60 years. Of the 125 patients, 32 (25.6%) were deficient, 49 (39.2%) were insufficient and 44 (35.2%) were sufficient in vitamin D at the time of diagnosis. The median survival in deficient, insufficient and sufficient cohorts was 47.8, 44.0 and 52.6 months respectively (p = 0.60). On univariate analysis, four variables demonstrated a statistically significant association with survival: nutritional status, bone metastasis, corrected serum calcium and serum albumin (p<0.05 for all). On multivariate analysis, five variables demonstrated statistically significant associations with survival: hospital location, age, bone metastasis, serum albumin and corrected serum calcium (p<0.05 for all). Serum vitamin D status was not significant on either univariate or multivariate analysis.

CONCLUSION

Contrary to previously published research, we found no significant association between pre-treatment serum 25(OH)D and survival in newly diagnosed stage IV prostate cancer patients. The lack of a significant association between serum vitamin D and survival in our study could perhaps be due to the fact that the disease was far too advanced in our patients for vitamin D levels to have any impact on prognosis.

摘要

背景/目的:文献中的新证据表明,作为维生素D状态的标准指标,血清25-羟基维生素D[25(OH)D]与某些类型癌症的生存率之间存在正相关。我们在新诊断的IV期前列腺癌患者中研究了这种关系。

方法

2008年1月至2011年12月期间,在我们机构接受治疗前,对连续的125例新诊断的IV期前列腺癌患者进行了基线血清25(OH)D评估。我们使用了“缺乏(<20 ng/ml)”、“不足(20至32 ng/ml)”和“充足(>32 ng/ml)”的维生素D分类。在调整相关混杂因素后,使用Cox回归评估血清25(OH)D的预后意义。

结果

诊断时的平均年龄为60岁。在125例患者中,诊断时维生素D缺乏的有32例(25.6%),不足的有49例(39.2%),充足的有44例(35.2%)。缺乏、不足和充足组的中位生存期分别为47.8、44.0和52.6个月(p = 0.60)。单因素分析显示,有四个变量与生存率有统计学显著关联:营养状况、骨转移、校正血清钙和血清白蛋白(均p<0.05)。多因素分析显示,有五个变量与生存率有统计学显著关联:医院位置、年龄、骨转移、血清白蛋白和校正血清钙(均p<0.05)。血清维生素D状态在单因素或多因素分析中均无显著性。

结论

与先前发表的研究相反,我们发现新诊断的IV期前列腺癌患者治疗前血清25(OH)D与生存率之间无显著关联。我们的研究中血清维生素D与生存率缺乏显著关联,可能是因为我们的患者疾病进展过于严重,以至于维生素D水平对预后没有任何影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e0/4361634/f9af9a272d9d/pone.0119690.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验